Trial · NCT05049278
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Graft mean blood flow measured using transit time flowmetry | Intraoperative period | Mean blood flow (in mL/min) of the graft vessel that was measured using transit time flowmetry |
| Primary | Pulsatility of graft vessel measured using transit time flowmetry | Intraoperative period | Pulsatility of graft vessel, which is presented as pulsatility index in unitless, that was measured using transit time flowmetry |
| Primary | Diastolic filling of the graft vessel measured using transit time flowmetry | Intraoperative period | Diastolic filling (in percentage) of the graft vessel that was measured using transit time flowmetry |
| Secondary | Graft failure rate in patients received each vasopressor during surgery | Within seven days after surgery | The rate of graft failure in patients received each vasopressor during surgery |
| Secondary | Capillary filling time in patients received each vasopressor during surgery | Within seven days after surgery | Capillary filling time, which was measured by time to refill the capillary after compression, to evaluate the viability of the flap in patients received each vasopressor during surgery |
| Secondary | Skin necrosis rate in patients received each vasopressor during surgery | Within seven days after surgery | The rate of skin necrosis, which is evaluated by any changes in skin color by description of the color of the skin by clinicians, to evaluate the viability of the graft in patients received each vasopressor during surgery |
| Secondary | Rate of vascular thrombosis in patients received each vasopressor during surgery | Within seven days after surgery | The rate of arterial or venous complication by measure of skin color change or decrease in doppler flow or capillary refill to evaluate the viability of the graft in patients received each vasopressor during surgery |
| Secondary | Rate of wound infection or any wound problem in patients received each vasopressor during surgery | Within seven days after surgery | The rate of any wound complication including infection to evaluate wound complication after surgery in patients each vasopressor during surgery |
| Secondary | Amount of transfusion in patients received each vasopressor during surgery | Within seven days after surgery | Amount of transfusion to evaluate clinical outcomes in patients received each vasopressor during surgery |
| Secondary | Total amount of remifentanil infused during surgery in patients received each vasopressor | intraoperative period | The total amount of remifentanil infused during surgery to evaluate clinical outcomes and perioperative variables in patients received each vasopressor during surgery |
| Secondary | Total amount of inotropic agents or vasopressor during surgery in patients received each vasopressor | intraoperative period | The total amount of inotropic agents or vasopressor during surgery to evaluate clinical outcomes and perioperative variables in patients received each vasopressor during surgery |
| Secondary | Stroke volume during surgery in patients received each vasopressor | intraoperative period | Stroke volume (in mL) measured by FlowTrac parameters to evaluate the intraoperative hemodynamics in patients received each vasopressor |
| Secondary | Cardiac index during surgery in patients received each vasopressor | intraoperative period | Cardiac index (in L/min/m\^2) measured by FlowTrac parameters to evaluate the intraoperative hemodynamics in patients received each vasopressor |
| Secondary | Stroke volume variation during surgery in patients received each vasopressor | intraoperative period | Stroke volume variation (in percentage) measured by FlowTrac parameters to evaluate the intraoperative hemodynamics in patients received each vasopressor |
| Secondary | Serum lactate levels in patients received each vasopressor | Within seven days after surgery | Serum lactate levels (in mmol/L) to evaluate the postoperative variables and clinical outcomes in patients received each vasopressor during surgery |
| Secondary | Wound exploration rate in patients received each vasopressor during surgery | Until discharge | The rate of wound exploration as a measure of postoperative complication and graft failure to evaluate the flap outcome in patients received each vasopressor during surgery |
| Secondary | Reoperation rate in patients received each vasopressor during surgery | Until discharge | The rate of reoperation as a measure of postoperative complication and graft failure to evaluate the flap outcome in patients received each vasopressor during surgery |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05049278/registered